PHARMICELL Co., Ltd. was first established as Yuhaw trade Co., Ltd. which was a company manufacturing textile and clothes in 1968 and was listed on the securities market in 1988. After the previous company was acquired by the current management of Pharmicell in August 2009, it was transformed into a cutting-edge biotechnology company using stem cells.
Pharmicell is devoting itself to the development and commercialization of stem cell therapeutics for the conquest of incurable diseases such as cancer, brain and nervous system disorders, heart diseases that are the most fatal to human beings.
We came to have the leading research results and abundant clinical experiences by entering the Investigational New Drug(IND) of stem cell therapeutics for ischemic stroke, spinal cord injury and myocardial infarction and conducted the Sponsor-Investigator Trials and emergency clinical research on a variety of cancer, liver failure, pulmonary fibrosis, Parkinson's syndrome. As a result, we obtained the NDA(New Drug Application) approval(marketing) for Hearticellgram-AMI, which is a stem cell therapeutics for acute myocardial infarction(AMI), for the first time in the world in July 2011 and have played a leading role in the field of development and commercialization of stem cell therapeutics for the conquest of incurable diseases.
Pharmicell is planning to accelerate the development of stem cell therapeutics for acute ischemic stroke(IND-phase 3) and chronic spinal cord injury(IND-phase 2/3) with the experiences relating to the NDA approval of stem cell therapeutics for acute myocardial infarction. In addition, we will continuously launch stem cell therapeutics according to our new drug development pipeline to treat alcoholic cirrhosis, pulmonary fibrosis, and cancer under investigator's trials and thereby give hope to the patients who are suffering from these incurable diseases.
Moreover, we will contribute to the vitalization of the industry related to stem cells through commercialization of stem cell therapeutics, stem cell banking, cell media, CMO(Contract Manufacturing Organization), stem cell culturing media, cell processing equipment, cell transport box, manufacturing and quality control software by utilizing our know-how accumulated in the process of commercialization of stem cell therapeutics.
This company has secured the intellectual property rights through the registration of patent for stem cell differentiation technology(dendritic cell production technology for anticancer immune treatment and production technology of nerve cells for treatment of brain and nervous system disorders) in foreign countries(7 countries including the US and EU) in order to gain technological competitive edge in the global markets.